A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes
- 13 June 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 22 (7), 727-734
- https://doi.org/10.1038/nm.4127
Abstract
Lenalidomide, which is used to treat myelodysplastic syndrome, kills mutation-bearing hematopoietic cells by increasing expression of the G-protein-coupled receptor GPR68, leading to increased intracellular calcium concentrations and calpain activation. Despite the high response rates of individuals with myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)) to treatment with lenalidomide (LEN) and the recent identification of cereblon (CRBN) as the molecular target of LEN, the cellular mechanism by which LEN eliminates MDS clones remains elusive. Here we performed an RNA interference screen to delineate gene regulatory networks that mediate LEN responsiveness in an MDS cell line, MDSL. We identified GPR68, which encodes a G-protein-coupled receptor that has been implicated in calcium metabolism, as the top candidate gene for modulating sensitivity to LEN. LEN induced GPR68 expression via IKAROS family zinc finger 1 (IKZF1), resulting in increased cytosolic calcium levels and activation of a calcium-dependent calpain, CAPN1, which were requisite steps for induction of apoptosis in MDS cells and in acute myeloid leukemia (AML) cells. In contrast, deletion of GPR68 or inhibition of calcium and calpain activation suppressed LEN-induced cytotoxicity. Moreover, expression of calpastatin (CAST), an endogenous CAPN1 inhibitor that is encoded by a gene (CAST) deleted in del(5q) MDS, correlated with LEN responsiveness in patients with del(5q) MDS. Depletion of CAST restored responsiveness of LEN-resistant non-del(5q) MDS cells and AML cells, providing an explanation for the superior responses of patients with del(5q) MDS to LEN treatment. Our study describes a cellular mechanism by which LEN, acting through CRBN and IKZF1, has cytotoxic effects in MDS and AML that depend on a calcium- and calpain-dependent pathway.This publication has 37 references indexed in Scilit:
- ENCODE Data in the UCSC Genome Browser: year 5 updateNucleic Acids Research, 2012
- Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies RevisitedJournal of Clinical Oncology, 2012
- Regulated Expression of pH Sensing G Protein-Coupled Receptor-68 Identified through Chemical Biology Defines a New Drug Target for Ischemic Heart DiseaseACS Chemical Biology, 2012
- NetWalker: a contextual network analysis tool for functional genomicsBMC Genomics, 2012
- Molecular Action of Lenalidomide in Lymphocytes and Hematologic MalignanciesAdvances in Hematology, 2012
- Metabolic Acidosis Increases Intracellular Calcium in Bone Cells Through Activation of the Proton Receptor OGR1Journal of Bone and Mineral Research, 2009
- An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic SyndromePLoS Medicine, 2008
- Lenalidomide inhibits the malignant clone and up-regulates theSPARCgene mapping to the commonly deleted region in 5q− syndrome patientsProceedings of the National Academy of Sciences of the United States of America, 2007
- The calpains: modular designs and functional diversityGenome Biology, 2007
- Proton-sensing G-protein-coupled receptorsNature, 2003